GW572016 Studies - Now Recruiting

In December 2003, The United States FDA granted GlaxoSmithKline's compound GW572016(Lapatinib) fast-track status for treatment of certain patients with refractory advanced or metastatic breast cancer who have failed previous therapies.

Clinical trials testing this oral investigational medication are ongoing at more than 100 sites throughout the country, with the goal of recruiting more than 600 women for the studies.

If you are interested in participating in these studies, click the link on our Home Page or go to: www.4breastcancertrials.com

We share the common goal of finding better ways to treat breast cancer. Clinical trials are crucial to this process.

Hugs and well wishes
Christine

Dear Christine
Thanks for posting this information. I have looked at the site but cannot find a contact email. I wanted to find out if it there are any studies in Australia.

love
lindaw

Hi There, I am in Queensland and my onc is referring me to the Trial at the Mater in Brisbane. I found the info on the site Paul recommended. Good Luck.

Hugs Lyn